This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva fails to get immediate appeal in US antitrust case over Nuvigil

( November 6, 2024, 16:33 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals was denied leave to immediately appeal an order on dismissal of US claims accusing it of blocking access to generic version of the wakefulness drug Nuvigil. “This case—like many cases—involves challenging and substantial issues. And the court recognizes the discovery burdens of an antitrust lawsuit. But that’s not sufficient justification to certify questions for interlocutory appeal. Ultimately, the court concludes that the questions presented by defendants don’t satisfy the 28 U.S.C. § 1292(b) criteria,” US District Judge Daniel D. Crabtree said.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections